{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:39:29Z","timestamp":1792143569408,"version":"4.4.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["FDN148374"],"award-info":[{"award-number":["FDN148374"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["EGM141899"],"award-info":[{"award-number":["EGM141899"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["ENP161427"],"award-info":[{"award-number":["ENP161427"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antidepressant drugs are effective therapies for major depressive disorder; however, they are frequently associated with side effects. Although there is some evidence for a relationship between genetic variation and side effects, little is known regarding the role of dynamic molecular factors as moderators of side effects. The aim of this study was to assess microRNA (miRNA) changes associated with side effects during escitalopram treatment and their downstream effects on target gene expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total 160 patients with major depressive disorder from the CAN-BIND-1 cohort were included. Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram. We assessed the relationship between side effects and changes in peripheral expression of miRNAs between baseline and week 2. For miRNA whose expression changed, we used target prediction algorithms to identify putative messenger RNA (mRNA) targets and assessed their expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nausea was experienced by 42.5% of patients. We identified 45 miRNAs whose expression changed on initiation of escitalopram treatment, of which 10 displayed a negative association with intensity of nausea (miR15b-5p, miR17-5p, miR20a-5p, miR20b-5p, miR103a-3p, miR103b, miR106a-5p, miR182-5p, miR185-5p, and miR660-5p). Additionally, we found negative associations between 4 microRNAs (miR20a-5p, miR106a-5p, miR185-5p, miR660-5p) and mRNA targets. The expression of the miR185-5p target, CAMK2\u03b4 was significantly decreased [log 2 mean\u2009=\u2009\u22120.048 (0.233)] between weeks 0 and 2 (P\u2009=\u2009.01)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyz066","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:12:23Z","timestamp":1575645143000},"page":"88-95","source":"Crossref","is-referenced-by-count":19,"title":["Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report"],"prefix":"10.1093","volume":"23","author":[{"given":"Antoine","family":"Yrondi","sequence":"first","affiliation":[{"name":"McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-471X","authenticated-orcid":false,"given":"Laura M","family":"Fiori","sequence":"first","affiliation":[{"name":"McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benicio N","family":"Frey","sequence":"first","affiliation":[{"name":"McMaster University and St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond W","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda M","family":"MacQueen","sequence":"first","affiliation":[{"name":"University of Calgary Hotchkiss Brain Institute, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roumen","family":"Milev","sequence":"first","affiliation":[{"name":"Providence Care Hospital, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, Ontario, Canada"},{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A","family":"Foster","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney H","family":"Kennedy","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University Health Network, Krembil Research Institute, University of Toronto, Toronto, Ontario, Canada"},{"name":"St Michael\u2019s Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide, Studies, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Turecki","sequence":"first","affiliation":[{"name":"McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"2020032608374979100_CIT0001","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1038\/tp.2012.57","article-title":"Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D","volume":"2","author":"Adkins","year":"2012","journal-title":"Transl Psychiatry"},{"key":"2020032608374979100_CIT0002","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00702-016-1585-7","article-title":"Pharmacogenetics of citalopram-related side effects in children with depression and\/or anxiety disorders","volume":"123","author":"Amitai","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"2020032608374979100_CIT0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0971-5916.162094","article-title":"Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: a preliminary study","volume":"142","author":"Basu","year":"2015","journal-title":"Indian J Med Res"},{"key":"2020032608374979100_CIT0004","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.euroneuro.2013.05.001","article-title":"Side effects of antidepressants during long-term use in a naturalistic setting","volume":"23","author":"Bet","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020032608374979100_CIT0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/tpj.2015.38","article-title":"A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort","volume":"16","author":"Bet","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"2020032608374979100_CIT0006","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/gb-2010-11-8-r90","article-title":"Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites","volume":"11","author":"Betel","year":"2010","journal-title":"Genome Biol"},{"key":"2020032608374979100_CIT0007","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/bioinformatics\/bts587","article-title":"ncPRO-seq: a tool for annotation and profiling of ncRNAs in sRNA-seq data","volume":"28","author":"Chen","year":"2012","journal-title":"Bioinformatics"},{"key":"2020032608374979100_CIT0008","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"2020032608374979100_CIT0009","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S003329171100239X","article-title":"Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D","volume":"42","author":"Clark","year":"2012","journal-title":"Psychol Med"},{"key":"2020032608374979100_CIT0010","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00213-014-3467-8","article-title":"Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals","volume":"231","author":"Crawford","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"2020032608374979100_CIT0011","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.encep.2016.05.006","article-title":"[Antidepressant and tolerance: determinants and management of major side effects]","volume":"42","author":"David","year":"2016","journal-title":"Encephale"},{"key":"2020032608374979100_CIT0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00228-013-1582-9","article-title":"Risk factors for non-adherence to antidepressant treatment in patients with mood disorders","volume":"70","author":"De las Cuevas","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2020032608374979100_CIT0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2165\/00002512-200825060-00004","article-title":"Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly","volume":"25","author":"Draper","year":"2008","journal-title":"Drugs Aging"},{"key":"2020032608374979100_CIT0014","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nmeth.3485","article-title":"miRWalk2.0: a comprehensive atlas of microRNA-target interactions","volume":"12","author":"Dweep","year":"2015","journal-title":"Nat Methods"},{"key":"2020032608374979100_CIT0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archpsyc.65.5.513","article-title":"Population-based study of first onset and chronicity in major depressive disorder","volume":"65","author":"Eaton","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"2020032608374979100_CIT0016","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1523\/JNEUROSCI.05-12-03270.1985","article-title":"Regional distribution of type II Ca2+\/calmodulin-dependent protein kinase in rat brain","volume":"5","author":"Erondu","year":"1985","journal-title":"J Neurosci"},{"key":"2020032608374979100_CIT0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020032608374979100_CIT0018","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ijnp\/pyx034","article-title":"Investigation of miR-1202, miR-135a, and miR-16 in major depressive disorder and antidepressant response","volume":"20","author":"Fiori","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"2020032608374979100_CIT0019","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/bs.pmbts.2018.04.004","article-title":"Using epigenetic tools to investigate antidepressant response","volume":"158","author":"Fiori","year":"2018","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2020032608374979100_CIT0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jagp.2013.07.003","article-title":"Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial","volume":"22","author":"Garfield","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"2020032608374979100_CIT0021","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of Adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2020032608374979100_CIT0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/gm351","article-title":"Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response","volume":"4","author":"Hodgson","year":"2012","journal-title":"Genome Med"},{"key":"2020032608374979100_CIT0023","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4088\/JCP.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate","volume":"65","author":"Hu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2020032608374979100_CIT0024","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev.biochem.71.110601.135410","article-title":"Neuronal CA2+\/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function","volume":"71","author":"Hudmon","year":"2002","journal-title":"Annu Rev Biochem"},{"key":"2020032608374979100_CIT0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/acps.12301","article-title":"Quality of life in major depressive disorder before\/after multiple steps of treatment and one-year follow-up","volume":"131","author":"IsHak","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"2020032608374979100_CIT0026","doi-asserted-by":"crossref","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"2020032608374979100_CIT0027","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12202","article-title":"Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: a CAN-BIND-1 Report","volume":"80","author":"Kennedy","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2020032608374979100_CIT0028","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The human genome browser at UCSC","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res"},{"key":"2020032608374979100_CIT0029","doi-asserted-by":"crossref","first-page":"D152","DOI":"10.1093\/nar\/gkq1027","article-title":"miRBase: integrating microRNA annotation and deep-sequencing data","volume":"39","author":"Kozomara","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2020032608374979100_CIT0030","doi-asserted-by":"crossref","first-page":"D68","DOI":"10.1093\/nar\/gkt1181","article-title":"miRBase: annotating high confidence microRNAs using deep sequencing data","volume":"42","author":"Kozomara","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2020032608374979100_CIT0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"2020032608374979100_CIT0032","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2020032608374979100_CIT0033","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"2020032608374979100_CIT0034","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/frne.1994.1012","article-title":"The area postrema and vomiting","volume":"15","author":"Miller","year":"1994","journal-title":"Front Neuroendocrinol"},{"key":"2020032608374979100_CIT0035","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","article-title":"A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes","volume":"126","author":"Miranda","year":"2006","journal-title":"Cell"},{"key":"2020032608374979100_CIT0036","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2020032608374979100_CIT0037","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00002512-199507030-00004","article-title":"Recent advances in geriatric psychopharmacology","volume":"7","author":"Naranjo","year":"1995","journal-title":"Drugs Aging"},{"key":"2020032608374979100_CIT0038","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"2020032608374979100_CIT0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0447.1997.tb05956.x","article-title":"Mirtazapine: pharmacology in relation to adverse effects","volume":"391","author":"Nutt","year":"1997","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2020032608374979100_CIT0040","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1261\/rna.5248604","article-title":"Fast and effective prediction of microRNA\/target duplexes","volume":"10","author":"Rehmsmeier","year":"2004","journal-title":"Rna"},{"key":"2020032608374979100_CIT0041","doi-asserted-by":"crossref","first-page":"e1000426","DOI":"10.1371\/journal.pbio.1000426","article-title":"Structure of the CaMKIIdelta\/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation","volume":"8","author":"Rellos","year":"2010","journal-title":"Plos Biol"},{"key":"2020032608374979100_CIT0042","first-page":"10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","author":"Sackeim","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2020032608374979100_CIT0043","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2015.14050680","article-title":"ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial","volume":"172","author":"Schatzberg","year":"2015","journal-title":"Am J Psychiatry"},{"key":"2020032608374979100_CIT0044","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2020032608374979100_CIT0045","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s13059-014-0509-9","article-title":"Lighter: fast and memory-efficient sequencing error correction without counting","volume":"15","author":"Song","year":"2014","journal-title":"Genome Biol"},{"key":"2020032608374979100_CIT0046","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr"},{"key":"2020032608374979100_CIT0047","doi-asserted-by":"crossref","first-page":"b2880","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration","volume":"339","author":"Stone","year":"2009","journal-title":"Bmj"},{"key":"2020032608374979100_CIT0048","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00018-008-8086-2","article-title":"Ca(2+)\/calmodulin-dependent protein kinases","volume":"65","author":"Swulius","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"2020032608374979100_CIT0049","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2012.10.030","article-title":"Contribution of common genetic variants to antidepressant response","volume":"73","author":"Tansey","year":"2013","journal-title":"Biol Psychiatry"},{"key":"2020032608374979100_CIT0050","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis","volume":"159","author":"Trindade","year":"1998","journal-title":"Cmaj"},{"key":"2020032608374979100_CIT0051","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1192\/bjp.bp.108.061960","article-title":"Adverse reactions to antidepressants","volume":"195","author":"Uher","year":"2009","journal-title":"Br J Psychiatry"},{"key":"2020032608374979100_CIT0052","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/070674370204700208","article-title":"Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine","volume":"47","author":"Vanderkooy","year":"2002","journal-title":"Can J Psychiatry"},{"key":"2020032608374979100_CIT0053","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4068\/cmj.2018.54.2.101","article-title":"Addressing the side effects of contemporary antidepressant drugs: a comprehensive review","volume":"54","author":"Wang","year":"2018","journal-title":"Chonnam Med J"},{"key":"2020032608374979100_CIT0054","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11319480-000000000-00000","article-title":"Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis","volume":"24","author":"Watanabe","year":"2010","journal-title":"CNS Drugs"},{"key":"2020032608374979100_CIT0055","doi-asserted-by":"crossref","first-page":"e104718","DOI":"10.1371\/journal.pone.0104718","article-title":"Serotonin 5-HT3 receptor-mediated vomiting occurs via the activation of Ca2+\/CaMKII-dependent ERK1\/2 signaling in the least shrew (Cryptotis parva)","volume":"9","author":"Zhong","year":"2014","journal-title":"Plos One"},{"key":"2020032608374979100_CIT0056","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2015.11.023","article-title":"Thapsigargin-induced activation of Ca(2+)-CaMKII-ERK in brainstem contributes to substance P release and induction of emesis in the least shrew","volume":"103","author":"Zhong","year":"2016","journal-title":"Neuropharmacology"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyz066\/31700384\/pyz066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/2\/88\/32967721\/pyz066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/2\/88\/32967721\/pyz066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T17:14:23Z","timestamp":1612977263000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/2\/88\/5670827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyz066","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,12,10]]}}}